Active Immunotherapy in cancer – Current Status_Crimson Publishers

Active Immunotherapy in cancer – Current Status by Bakulesh Khamar in Journal of cancer research and clinical oncology

 
 Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor works by reducing tumor induced immunosuppression and thereby utilizing pre-existing immune response. Adoptive cell therapy (ACT) is a type of personalized therapy wherein cells are harvested from a patient, expanded and reintroduced. The T cells are genetically modified in chimeric antigen receptor T cell (CAR-T) therapy while tumor infiltrating cells are used in in ACT and dendritic cells are used in dendritic cell (DC) vaccine. Vaccine induces T cell response against the antigen of interest. T cells available following single administration are higher in ACT compared to vaccine approach. CAR-T cells are found useful in refractory large B-cell lymphoma and refractory large B-cell precursor acute lymphoblastic leukemia. ACT is found useful in melanoma. Vaccines are approved for melanoma as a monotherapy and for non-small cell lung cancer in combination with chemotherapy.

 https://crimsonpublishers.com/nacs/fulltext/NACS.000513.php

Novel Approaches in Cancer Study: Crimson Publishers
For more open access journals in crimson publishers please click on link: https://crimsonpublishers.com
For More Articles on Journal of cancer research and clinical oncology Please click on: https://crimsonpublishers.com/nacs/
 

Comments

Post a Comment

Popular posts from this blog

Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme_Crimson Publishers

Image
  Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme by Siddharth Shah in  in Novel Approaches in Cancer Study Abstract Glioblastoma Multiforme (GBM, WHO grade IV) is one of the most aggressive, invasive, and lethal intracranial neoplasms, with a low post-diagnosis survival rate. Standard-of-care treatment regimens involving maximal surgical resection, radiotherapy, and genetic anti-tumor compounds like Temozolomide have only been marginally effective in improving overall survival and quality of life. Cell fusion, autophagy, and other complex biological processes affecting GBM pathophysiology are being studied to improve GBM treatment. This paper therefore focuses on oncolytic virus therapy combined with surgical resection, photodynamic therapy, and novel gene therapy, demonstrating how GBM treatment for patients could result in immediate and authentic tumor cytotoxicity and removal, rather than treatment of recurrent GBM. Standard therapy for GBM,...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases

Abstract Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tumor environment. Therefore, the purpose of this study is to correlate a possible contribution of the Pi release in the tumor microenvironment by ecto-nucleotidases and ecto-phosphatases, concomitant to the regulation of Pi extracellular pool by specific Pi...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases_Crimson Publishers

Image
Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases by Marco Antonio Lacerda-Abreu and José Roberto Meyer- Fernandes in Journal of Cancer Research Crimson Publishers _  Novel Approaches in Cancer Study Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tu...
Read more